Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Hepatitis B, Chronic

Study type: Observational

Funder types: Industry

Identifiers

NCT01155427

AI463-186

Details and patient eligibility

About

The purpose of this study is to support the clinical value of entecavir by assessing the relationship between viral load and histological improvement.

Full description

Systematic review of prospective clinical trials

Enrollment: 100 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with CHB diagnosis and no co-infection with Hep A, Hep C, Hep D, or HIV
• Age 16 years or older
• No post-transplant patients
• RCT, non-randomized trials, prospective cohort studies, prospectively analyses case series published since 2003
• At least one arm of trial must include monotherapy with entecavir, lamivudine, tenofovir, adefovir, or telbivudine
• Study arms must include at least 10 patients
• Follow-up of at least 48 weeks
• Published results available in English language

Exclusion criteria

• N/A

Trial design

100 participants in 5 patient groups

entecavir

Description:

Patients initiating special antiviral treatments for CHB

tenofovir

Description:

Patients initiating special antiviral treatments for CHB

lamivudine

Description:

Patients initiating special antiviral treatments for CHB

telbivudine

Description:

Patients initiating special antiviral treatments for CHB

adefovir

Description:

Patients initiating special antiviral treatments for CHB